Vialwirebiotech, curated
July 22, 2026, 12:34 PM
June 12, 2026
- 12:00 PM · Pharmaceutical Executive12:00 PM<![CDATA[Zepzelca Fails to Meet Main Goal of Phase III Lagoon Trial in Second-Line Small Cell Lung Cancer]]> — Pharmaceutical Executive
- 12:00 PM · BioWorld12:00 PMStreet canvu MBX phase II HP data more than one way — BioWorld
- 12:00 PM · BioWorld12:00 PMChina partnerships drive biopharma’s biggest deal month since 2023 — BioWorld
- 9:31 AM · BioPharma Dive9:31 AMRapport ‘fully prepared’ to launch seizure drug solo, CEO says — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMApplied Biologics begins osteoarthritis research program — BioWorld
- 9:00 AM · BioWorld9:00 AMThryv Therapeutics synthesizes SGK1 inhibitors — BioWorld
- 9:00 AM · BioWorld
- 9:00 AM · BioWorld9:00 AMShanghai Ruotuo Biotechnology discovers new anti-EGFR/HER3 ADCs — BioWorld
- 9:00 AM · BioWorld9:00 AMHengrui Pharmaceuticals reports new BCL6 degradation inducers — BioWorld
- 9:00 AM · BioWorld9:00 AMChangchun Genescience Pharmaceuticals identifies new FGFR2/3 inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMFortvita and Innovent patent new anti-TROP2/B7-H4 ADCs — BioWorld
- 9:00 AM · BioWorld9:00 AMJW Pharmaceutical’s DDC-02 improves cognitive function — BioWorld
- 7:00 AM · Drug Discovery World7:00 AMLaverock reports positive data from oncology programmes — Drug Discovery World
- 5:46 AM · Pharmaceutical Technology5:46 AMChina’s NMPA approves Akeso’s gumokimab for plaque psoriasis — Pharmaceutical Technology
- 5:00 AM · MIT Technology Review5:00 AMWhy “reprogramming” is the buzziest approach to reversing aging right now — MIT Technology Review
- 4:39 AM · Pharmaceutical Technology4:39 AMFDA grants priority review for Roche’s Tecentriq combo sBLA — Pharmaceutical Technology
June 11, 2026
- 9:04 PM · TechCrunch
- 5:15 PM · SCMP — Tech5:15 PMBiotech firm WuXi sues US over allegations it supports China’s military — SCMP — Tech
- 2:33 PM · STAT News2:33 PMNonprofit buys experimental cancer drug to maintain patient access — STAT News
- 1:06 PM · STAT News1:06 PMSTAT+: Abridge inks deals with Nvidia and Lilly — STAT News
- 12:00 PM · BioWorld12:00 PMDermasensor receives CE mark for skin cancer detection device — BioWorld
- 12:00 PM · BioWorld12:00 PMEnliven’s phase I CML data Enable phase III with BCR/ABL1 bid — BioWorld
- 12:00 PM · BioWorld12:00 PMAnother FDA no for Camurus’ monthly acromegaly drug Oclaiz — BioWorld
- 11:57 AM · Bloomberg — Technology11:57 AMNovo Detects Unauthorized Access to Some Internal IT Systems — Bloomberg — Technology
- 11:55 AM · BioPharma Dive11:55 AMSummit pulls $500M share sale a day after announcing it — BioPharma Dive
- 11:29 AM · BioPharma Dive11:29 AMSensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy — BioPharma Dive
- 11:00 AM · BBC — Health11:00 AMWegovy weight-loss pill approved in UK — BBC — Health
- 10:18 AM · BioPharma Dive10:18 AMNovartis RNA drug acquired in $12B Avidity deal notches a trial win — BioPharma Dive
- 9:54 AM · Drug Discovery World9:54 AMDaltonTx launches AI drug discovery platform — Drug Discovery World
- 9:27 AM · BioPharma Dive9:27 AMJ&J looks to widen Imaavy’s use; $300M backs rare disease drug launch — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMScenic Biotech joins MJFF LITE program to expand PLA2G15 research — BioWorld
- 9:00 AM · BioWorld9:00 AMEthyreal Bio launches with focus on thyroid diseases — BioWorld
- 9:00 AM · BioWorld9:00 AMT-Curx gains trial clearance for Siglec-6-targeted TCX-001 — BioWorld
- 8:05 AM · STAT News8:05 AMSTAT+: Enliven Therapeutics’ leukemia drug shows promise in new study — STAT News
- 6:24 AM · Drug Discovery World6:24 AMBead BioPharma emerges from stealth with novel drug platform — Drug Discovery World
- 5:35 AM · Pharmaceutical Technology5:35 AMXtalPi enters $400m partnership for small molecule therapy for GPCR target — Pharmaceutical Technology
- 5:35 AM · Pharmaceutical Technology5:35 AMBeren pockets $300m to take Niemann-Pick disease therapy to market — Pharmaceutical Technology
- 3:56 AM · Pharmaceutical Technology3:56 AMEMA validates Bayer’s asundexian application for ischaemic stroke — Pharmaceutical Technology